## Toni Celià -Terrassa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2689575/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer, 2022, 3, 355-370.	5.7	21
2	p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis. Nature Communications, 2022, 13, .	5.8	17
3	Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. Journal of Clinical Investigation, 2021, 131, .	3.9	48
4	Cell memory of epithelial-mesenchymal plasticity in cancer. Current Opinion in Cell Biology, 2021, 69, 103-110.	2.6	11
5	Cancer Stem Cells and Epithelial-to-Mesenchymal Transition in Cancer Metastasis. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036905.	2.9	98
6	Insights into the Multi-Dimensional Dynamic Landscape of Epithelial–Mesenchymal Plasticity through Inter-Disciplinary Approaches. Journal of Clinical Medicine, 2020, 9, 1624.	1.0	1
7	Dynamics of Phenotypic Heterogeneity Associated with EMT and Stemness during Cancer Progression. Journal of Clinical Medicine, 2019, 8, 1542.	1.0	109
8	Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. Cancer Cell, 2019, 35, 64-80.e7.	7.7	124
9	Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nature Communications, 2018, 9, 5005.	5.8	144
10	Notch ligand Dll1 mediates cross-talk between mammary stem cells and the macrophageal niche. Science, 2018, 360, .	6.0	144
11	Mammary Stem Cells and Breast Cancer Stem Cells: Molecular Connections and Clinical Implications. Biomedicines, 2018, 6, 50.	1.4	13
12	Metastatic niche functions and therapeutic opportunities. Nature Cell Biology, 2018, 20, 868-877.	4.6	129
13	Mouse genomic screen reveals novel host regulator of metastasis. Genome Biology, 2017, 18, 31.	3.8	3
14	Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. Journal of Hepatology, 2017, 67, 246-254.	1.8	52
15	Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a–LCOR axis. Nature Cell Biology, 2017, 19, 711-723.	4.6	83
16	Distinctive properties of metastasis-initiating cells. Genes and Development, 2016, 30, 892-908.	2.7	277
17	Metabolic Reprogramming and Dependencies Associated with Epithelial Cancer Stem Cells Independent of the Epithelial-Mesenchymal Transition Program. Stem Cells, 2016, 34, 1163-1176.	1.4	77
18	SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Molecular Cancer, 2014, 13, 237.	7.9	60

#	Article	IF	CITATIONS
19	Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1. Oncogene, 2014, 33, 1124-1134.	2.6	27
20	Acid ceramidase as a therapeutic target in metastatic prostate cancer. Journal of Lipid Research, 2013, 54, 1207-1220.	2.0	61
21	Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. Journal of Clinical Investigation, 2012, 122, 1849-1868.	3.9	401
22	Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nature Medicine, 2011, 17, 1101-1108.	15.2	552